![Laura Sepp-Lorenzino](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Laura Sepp-Lorenzino
Director/Board Member at
TAYSHA GENE THERAPIES, INC.
Net worth: 746 535 $ as of 2026-05-30
Profile
Dr. Laura Sepp-Lorenzino is an Independent Director at Taysha Gene Therapies, Inc. and a Chief Scientific Officer & Executive VP at Intellia Therapeutics, Inc. She is on the Board of Directors at Taysha Gene Therapies, Inc. Dr. Sepp-Lorenzino was previously employed as a VP, Head-Nucleic Acid Therapies & Research by Vertex Pharmaceuticals, Inc., a Vice President by Alnylam Pharmaceuticals, Inc., and an Executive Director & Head-RNA Therapeutics by Merck & Co., Inc. She received her undergraduate degree from Universidad de Buenos Aires, a graduate degree from New York University and a doctorate degree from New York University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-05-31 | 127,178 ( 0.05% ) | 746 535 $ | 2026-05-30 | |
| 2026-04-27 | 0 ( -.--% ) | - $ | 2026-05-30 |
Laura Sepp-Lorenzino active positions
| Companies | Position | Start |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Director/Board Member | 2020-11-22 |
| LEXEO THERAPEUTICS, INC. | Director/Board Member | 2026-04-27 |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit forum for research and development of oligonucleotide therapeutics | Director/Board Member | - |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Director/Board Member | - |
Former positions of Laura Sepp-Lorenzino
| Companies | Position | End |
|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2025-01-12 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 2019-04-30 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2017-08-31 |
| MERCK & CO., INC. | Director/Board Member | 2014-02-28 |
Training of Laura Sepp-Lorenzino
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
85
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Vertex Pharmaceuticals, Inc.
 Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
New York University
 New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Universidad de Buenos Aires
 Universidad de Buenos Aires Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit forum for research and development of oligonucleotide therapeutics | Commercial Services |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Health Services |
Intellia Therapeutics, Inc.
 Intellia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel and potentially curative therapeutics | Health Technology |
Taysha Gene Therapies, Inc.
 Taysha Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes adeno-associated viruses-based gene therapies for the treatment of monogenic diseases of the central nervous system | Health Technology |
Lexeo Therapeutics Inc
 Lexeo Therapeutics Inc BiotechnologyHealth Technology Develops gene therapy to treat genetic diseases | Health Technology |
- Stock Market
- Insiders
- Laura Sepp-Lorenzino
Choose MarketScreener 
